ClinicalTrials.gg
RecruitingNCT05800210Updated Jun 4, 2026

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

A Phase 2 interventional study of Miltenyi CliniMACS Prodigy ® system in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Juvenile Myelomonocytic Leukemia, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 6 Months to 39 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University of Florida · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
6 Months to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Planned enrollment
858th of 1,269
20 · median 35
Started
2024
with 41 others
Phase 2
426 of 1,545
40 open now
Primary completion
2027-05
later than 118 of 272 live
Registered
1,418th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 858th largest by planned enrollment of the 1,269 interventional ones that give a count, is one of 42 that started in 2024, is one of 426 in phase 2, reaches primary completion later than 118 of the 272 other live ones, and was the 1,418th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 6 Months to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Juvenile Myelomonocytic Leukemia
  • Myelodysplastic Syndromes
  • Chronic Myeloid Leukemia
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Hodgkin

Keywords

  • hematologic malignancy
  • GVHD
  • stem cell transplantation
  • graft manipulation
04

Who can participate

Ages eligible
6 Months to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Children, Adolescents, Young adults (ages 6 months to ≤39 years) with the following diseases may be eligible:

i. ALL

  1. ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (≤15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (≥0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (≤44 chromosomes)) in first remission
  2. ALL in second remission and beyond

ii. AML

  1. History of AML induction/reinduction Failure (≤15% blasts at time of registration)
  2. AML in CR1 with poor cytogenetics (i.e., 12p, 5a, -7, FLT3 mutation/duplication, t(9;11) and others)
  3. AML with persistent minimal residual disease (MRD) in CR1(≥0.01% on flow or persistent abnormal karyotype detected by cytogenetics)
  4. AML CR2 or beyond
  5. AML in relapse but ≤15% bone marrow leukemia blasts
  6. Therapy-related AML

iii. Juvenile MyeloMonocytic Leukemia (JMML)

  1. JMML in CR1 without CBL mutation
  2. JMML with recurrence of disease with or without CBL mutation
  3. JMML CR2 or beyond

iv. Chronic Myeloid Leukemia (CML)

1. CML in CR with regard to blast crisis

v. High Risk Myelodysplastic syndrome (MDS)

vi. Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL)

  1. HL or NHL with a history of induction failure
  2. HL or NHL in PR1 or PR2
  3. HL or NHL in CR2 or subsequent remission

B. Subjects must not have more than one active at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen [as determined by the treating physician and approved by the PI] may be included).

C. HLA-matched (5-6/6) sibling donor, matched (8-10/10) unrelated donor available for stem cell donation, haplo-identical related donor (at least one full haplotype must be matched).

D. or Lansky score ≥60% at the time of enrollment. Karnofsky scores must be used for patients >16 years of age and Lansky scores for patients ≤16 years of age.

E. Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:

i. Pulmonary: , FVC, and corrected DLCO must all be ≥ 60% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.

ii. Renal: or radioisotope ≥60 mL/min/1.73 m2 or a serum creatinine based on age/gender

iii. Cardiac: Shortening fraction of ≥ 27% by echocardiogram) or of ≥ 50% by echocardiogram or radionuclide scan (MUGA).

iv. Hepatic: (AST) or SGPT (ALT) \< 5 x (ULN) for age. Conjugated \< 2.5 mg/dL, unless attributable to Gilbert's Syndrome.

F. Written obtained from the subject or guardian and the subject agrees to comply with all the study-related procedures.

G. Subjects of (SOCBP) must be using an adequate method of to avoid pregnancy throughout the study and for at least 8 weeks after the last dose of study drug to minimize the risk of pregnancy.

H. Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 8 weeks following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

A. Patients with documented uncontrolled infection

B. Patients who have received hematopoietic stem cell transplantation within 6 months, unless being done as a boost.

C. Patients with active ≥Grade 2 aGVHD.

D. Demonstrated lack of compliance with medical care.

E. Females or males of who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after the last dose of study drug.

F. Females who are known to be pregnant or breastfeeding.

G. History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.

H. Prisoners or subjects who are incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Allogeneic stem cell transplant with ⍺/β CD3+ T-cell and CD19+ B-cell depleted graft

    Device: Miltenyi CliniMACS Prodigy ® system

Interventions

  • DeviceMiltenyi CliniMACS Prodigy ® system

    Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.

06

What researchers measure

Primary outcomes

  1. Acute graft versus host disease (aGVHD) incidence

    Compare the incidence of grade II to IV aGVHD following allogeneic stem cell trasplantation utilizing α/β CD3+ T-cell and CD19+ B-cell depletion compared to historical controls by day +100

    Time frame: 100 days

Secondary outcomes

  1. Event-free survival

    Evaluate the event-free survival, which is defined as being alive and without evidence of disease relapse

    Time frame: 2 years

  2. Overall survival

    Evaluate the overall survival

    Time frame: 2 years

  3. Probability of hematopoietic engraftment

    Determine the probability of hematopoietic engraftment, as measured by the presence of donor chimerism \>95% by day 100

    Time frame: 100 days

  4. Cytomegalovirus (CMV) viremia incidence

    Determine the incidence of CMV viremia. Viremia is defined as \>1000copies/mL present on at least 2 weekly tests or requiring therapy.

    Time frame: 1 year

  5. Epstein-Barr virus (EBV) viremia incidence

    Determine the incidence of EBV viremia. Viremia is defined as \>1000copies/mL present on at least 2 weekly tests or requiring therapy.

    Time frame: 1 year

  6. Adenovirus viremia incidence

    Determine the incidence of adenovirus viremia. Viremia is defined as \>1000copies/mL present on at least 2 weekly tests or requiring therapy.

    Time frame: 1 year

  7. Post-transplant lymphoproliferative disorder (PTLD) incidence

    Determine the incidence of PTLD

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 36 months is below that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Apr 5, 2023
StartActual
May 3, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05800210
Collaborators
Florida Department of Health, Ocala Royal Dames for Cancer Research
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
May 3, 2024
Primary completion
May 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Jun 4, 2026

Study contacts

Beate Greer
Contact
bgreer01@ufl.edu
352-294-8744
Jordan Milner, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion